{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:18:33Z","timestamp":1787318313430,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Zhejiang Province","award":["LQ19H300002"],"award-info":[{"award-number":["LQ19H300002"]}]},{"name":"the Natural Science Foundation of Zhejiang Province","award":["LY21G300004"],"award-info":[{"award-number":["LY21G300004"]}]},{"DOI":"10.13039\/501100001809","name":"The Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273996"],"award-info":[{"award-number":["82273996"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The major safety concern of the clinical application of wild type FGF19 (FGF19\n                      <jats:sup>WT<\/jats:sup>\n                      ) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19\n                      <jats:sup>\u0394KLB<\/jats:sup>\n                      , which have same effects on glycemic control and bile acid production but much less mitogenic activity. However, it remains unclear as to whether FGF19\n                      <jats:sup>\u0394KLB<\/jats:sup>\n                      ameliorates intrahepatic cholestasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that, similar to that of FGF19\n                      <jats:sup>WT<\/jats:sup>\n                      , the chronic administration of FGF19\n                      <jats:sup>\u0394KLB<\/jats:sup>\n                      protects mice from cholestatic liver injury in these two models. The therapeutic benefits of FGF19\n                      <jats:sup>\u0394KLB<\/jats:sup>\n                      on cholestatic liver damage are attributable, according to the following mechanistic investigation, to the reduction of BA production, liver inflammation, and fibrosis. More importantly, FGF19\n                      <jats:sup>\u0394KLB<\/jats:sup>\n                      did not induce any tumorigenesis effects during its prolonged treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Together, our findings raise hope that FGF19\n                      <jats:sup>\u0394KLB<\/jats:sup>\n                      may represent a useful therapeutic strategy for the treatment of intrahepatic cholestasis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12896-023-00810-9","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:02:24Z","timestamp":1696327344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Engineered FGF19\u0394KLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-\/- mice model"],"prefix":"10.1186","volume":"23","author":[{"given":"Lu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlou","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","volume":"17","author":"A de Vallim","year":"2013","unstructured":"de Vallim A, Tarling TQ, E. J., Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17:657\u201369. https:\/\/doi.org\/10.1016\/j.cmet.2013.03.013.","journal-title":"Cell Metab"},{"key":"810_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","volume":"66","author":"T Li","year":"2014","unstructured":"Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66:948\u201383. https:\/\/doi.org\/10.1124\/pr.113.008201.","journal-title":"Pharmacol Rev"},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/hep.22771","volume":"49","author":"FG Schaap","year":"2009","unstructured":"Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 2009;49:1228\u201335. https:\/\/doi.org\/10.1002\/hep.22771.","journal-title":"Hepatology"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.28991","volume":"65","author":"M Trauner","year":"2017","unstructured":"Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology. 2017;65:1393\u2013404. https:\/\/doi.org\/10.1002\/hep.28991.","journal-title":"Hepatology"},{"key":"810_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/164_2019_231","volume":"256","author":"V Keitel","year":"2019","unstructured":"Keitel V, Droge C, Haussinger D. Targeting FXR in Cholestasis. Handb Exp Pharmacol. 2019;256:299\u2013324. https:\/\/doi.org\/10.1007\/164_2019_231.","journal-title":"Handb Exp Pharmacol"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin SI, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17:225\u201335. https:\/\/doi.org\/10.1016\/j.cmet.2013.01.003.","journal-title":"Cell Metab"},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/hep.28826","volume":"64","author":"SR Kulkarni","year":"2016","unstructured":"Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. Hepatology. 2016;64:2151\u201364. https:\/\/doi.org\/10.1002\/hep.28826.","journal-title":"Hepatology"},{"key":"810_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000371670","volume":"33","author":"SA Kliewer","year":"2015","unstructured":"Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15\/19 pathway. Dig Dis. 2015;33:327\u201331. https:\/\/doi.org\/10.1159\/000371670.","journal-title":"Dig Dis"},{"key":"810_CR9","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.1074\/jbc.M808747200","volume":"284","author":"DJ Shin","year":"2009","unstructured":"Shin DJ, Osborne TF. FGF15\/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem. 2009;284:11110\u201320. https:\/\/doi.org\/10.1074\/jbc.M808747200.","journal-title":"J Biol Chem"},{"key":"810_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217\u201325. https:\/\/doi.org\/10.1016\/j.cmet.2005.09.001.","journal-title":"Cell Metab"},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1038\/ncomms7980","volume":"6","author":"RJ Perry","year":"2015","unstructured":"Perry RJ, et al. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Commun. 2015;6:6980. https:\/\/doi.org\/10.1038\/ncomms7980.","journal-title":"Nat Commun"},{"key":"810_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrgastro.2018.28","volume":"15","author":"INASH Dickson","year":"2018","unstructured":"Dickson INASH. Successful phase II trial of FGF19 analogue. Nat Rev Gastroenterol Hepatol. 2018;15:256. https:\/\/doi.org\/10.1038\/nrgastro.2018.28.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1038\/s41467-020-17363-6","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. An FGF15\/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis. Nat Commun. 2020;11:3612. https:\/\/doi.org\/10.1038\/s41467-020-17363-6.","journal-title":"Nat Commun"},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/CM9.0000000000001574","volume":"134","author":"JY Hu","year":"2021","unstructured":"Hu JY, et al. Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes. Chin Med J (Engl). 2021;134:2243\u20135. https:\/\/doi.org\/10.1097\/CM9.0000000000001574.","journal-title":"Chin Med J (Engl)"},{"key":"810_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, et al. First-in-human phase I study of Fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in Hepatocellular Carcinoma. Cancer Discov. 2019;9:1696\u2013707. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0555.","journal-title":"Cancer Discov"},{"key":"810_CR16","doi-asserted-by":"publisher","unstructured":"Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 signaling in Hepatocellular Carcinoma. Cells. 2019;8. https:\/\/doi.org\/10.3390\/cells8060536.","DOI":"10.3390\/cells8060536"},{"key":"810_CR17","doi-asserted-by":"publisher","first-page":"103672","DOI":"10.1016\/j.etap.2021.103672","volume":"86","author":"Z Chen","year":"2021","unstructured":"Chen Z, et al. Intrahepatic cholestasis induced by alpha-naphthylisothiocyanate can cause gut-liver axis disorders. Environ Toxicol Pharmacol. 2021;86:103672. https:\/\/doi.org\/10.1016\/j.etap.2021.103672.","journal-title":"Environ Toxicol Pharmacol"},{"key":"810_CR18","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1073\/pnas.0907812106","volume":"106","author":"X Wu","year":"2009","unstructured":"Wu X, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob\/ob mice. Proc Natl Acad Sci U S A. 2009;106:14379\u201384. https:\/\/doi.org\/10.1073\/pnas.0907812106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"810_CR19","doi-asserted-by":"publisher","first-page":"e33603","DOI":"10.1371\/journal.pone.0033603","volume":"7","author":"H Ge","year":"2012","unstructured":"Ge H, et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS ONE. 2012;7:e33603. https:\/\/doi.org\/10.1371\/journal.pone.0033603.","journal-title":"PLoS ONE"},{"key":"810_CR20","doi-asserted-by":"publisher","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","volume":"6","author":"J Luo","year":"2014","unstructured":"Luo J, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med. 2014;6:247ra100. https:\/\/doi.org\/10.1126\/scitranslmed.3009098.","journal-title":"Sci Transl Med"},{"key":"810_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrgastro.2014.148","volume":"11","author":"G Patman","year":"2014","unstructured":"Patman G. Liver: a variant of FGF19 protects the liver from cholestatic injury without inducing cancer. Nat Rev Gastroenterol Hepatol. 2014;11:579. https:\/\/doi.org\/10.1038\/nrgastro.2014.148.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"810_CR22","doi-asserted-by":"publisher","unstructured":"Walters JR, Appleby RN. A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism. Ann Transl Med. 2015;3. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.38.","DOI":"10.3978\/j.issn.2305-5839.2015.03.38"},{"key":"810_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coph.2017.09.008","volume":"37","author":"H Malhi","year":"2017","unstructured":"Malhi H, Camilleri M. Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases. Curr Opin Pharmacol. 2017;37:80\u20136. https:\/\/doi.org\/10.1016\/j.coph.2017.09.008.","journal-title":"Curr Opin Pharmacol"},{"key":"810_CR24","doi-asserted-by":"publisher","first-page":"17210","DOI":"10.1038\/s41598-018-35496-z","volume":"8","author":"RM Gadaleta","year":"2018","unstructured":"Gadaleta RM, et al. Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from Fibrosis and Hepatocarcinogenesis. Sci Rep. 2018;8:17210. https:\/\/doi.org\/10.1038\/s41598-018-35496-z.","journal-title":"Sci Rep"},{"key":"810_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41395-018-0042-7","volume":"113","author":"I Oduyebo","year":"2018","unstructured":"Oduyebo I, et al. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. Am J Gastroenterol. 2018;113:725\u201334. https:\/\/doi.org\/10.1038\/s41395-018-0042-7.","journal-title":"Am J Gastroenterol"},{"key":"810_CR26","doi-asserted-by":"publisher","first-page":"e21286","DOI":"10.1096\/fj.202002203R","volume":"35","author":"CM Williams","year":"2021","unstructured":"Williams CM, et al. Monomeric\/dimeric forms of Fgf15\/FGF19 show differential activity in hepatocyte proliferation and metabolic function. FASEB J. 2021;35:e21286. https:\/\/doi.org\/10.1096\/fj.202002203R.","journal-title":"FASEB J"},{"key":"810_CR27","doi-asserted-by":"publisher","first-page":"29025","DOI":"10.1073\/pnas.2010984117","volume":"117","author":"J Niu","year":"2020","unstructured":"Niu J, et al. Curtailing FGF19\u2019s mitogenicity by suppressing its receptor dimerization ability. Proc Natl Acad Sci U S A. 2020;117:29025\u201334. https:\/\/doi.org\/10.1073\/pnas.2010984117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"810_CR28","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1172\/JCI94029","volume":"127","author":"EJ Tarling","year":"2017","unstructured":"Tarling EJ, et al. RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism. J Clin Invest. 2017;127:3741\u201354. https:\/\/doi.org\/10.1172\/JCI94029.","journal-title":"J Clin Invest"},{"key":"810_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejphar.2005.03.039","volume":"515","author":"J Charoenteeraboon","year":"2005","unstructured":"Charoenteeraboon J, et al. Induction of human cholesterol 7alpha-hydroxylase in HepG2 cells by 2,4,6-trihydroxyacetophenone. Eur J Pharmacol. 2005;515:43\u20136. https:\/\/doi.org\/10.1016\/j.ejphar.2005.03.039.","journal-title":"Eur J Pharmacol"},{"key":"810_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejmech.2014.07.107","volume":"85","author":"X Liu","year":"2014","unstructured":"Liu X, et al. Activated AMPK explains hypolipidemic effects of sulfated low molecular weight guluronate on HepG2 cells. Eur J Med Chem. 2014;85:304\u201310. https:\/\/doi.org\/10.1016\/j.ejmech.2014.07.107.","journal-title":"Eur J Med Chem"},{"key":"810_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/hep.23708","volume":"52","author":"V Triantis","year":"2010","unstructured":"Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Hepatology. 2010;52:656\u201366. https:\/\/doi.org\/10.1002\/hep.23708.","journal-title":"Hepatology"},{"key":"810_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coph.2018.08.005","volume":"43","author":"M Piglionica","year":"2018","unstructured":"Piglionica M, Cariello M, Moschetta A. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19. Curr Opin Pharmacol. 2018;43:93\u20138. https:\/\/doi.org\/10.1016\/j.coph.2018.08.005.","journal-title":"Curr Opin Pharmacol"},{"key":"810_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/14767058.2018.1513483","volume":"33","author":"N Memon","year":"2020","unstructured":"Memon N, et al. Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates. J Matern Fetal Neonatal Med. 2020;33:987\u201392. https:\/\/doi.org\/10.1080\/14767058.2018.1513483.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"810_CR34","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"JY Chiang","year":"2009","unstructured":"Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50:1955\u201366. https:\/\/doi.org\/10.1194\/jlr.R900010-JLR200.","journal-title":"J Lipid Res"},{"key":"810_CR35","doi-asserted-by":"publisher","unstructured":"Pinto C, Ninfole E, Benedetti A, Marzioni M, Maroni L. Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10102772.","DOI":"10.3390\/cells10102772"},{"key":"810_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2010.09.004","volume":"139","author":"GM Hirschfield","year":"2010","unstructured":"Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology. 2010;139:1481\u201396. https:\/\/doi.org\/10.1053\/j.gastro.2010.09.004.","journal-title":"Gastroenterology"},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","volume":"127","author":"P Fickert","year":"2004","unstructured":"Fickert P, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127:261\u201374. https:\/\/doi.org\/10.1053\/j.gastro.2004.04.009.","journal-title":"Gastroenterology"},{"key":"810_CR38","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","volume":"63","author":"M Zhou","year":"2016","unstructured":"Zhou M, et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology. 2016;63:914\u201329. https:\/\/doi.org\/10.1002\/hep.28257.","journal-title":"Hepatology"},{"key":"810_CR39","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1002\/ptr.7086","volume":"35","author":"M Wen","year":"2021","unstructured":"Wen M, et al. Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis. Phytother Res. 2021;35:3799\u2013811. https:\/\/doi.org\/10.1002\/ptr.7086.","journal-title":"Phytother Res"},{"key":"810_CR40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jhep.2005.06.025","volume":"43","author":"Y Popov","year":"2005","unstructured":"Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-\/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005;43:1045\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2005.06.025.","journal-title":"J Hepatol"},{"key":"810_CR41","doi-asserted-by":"publisher","unstructured":"Kiriyama Y, Nochi H. The biosynthesis, signaling, and neurological functions of bile acids. Biomolecules. 2019;9. https:\/\/doi.org\/10.3390\/biom9060232.","DOI":"10.3390\/biom9060232"},{"key":"810_CR42","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","volume":"74","author":"M Zhou","year":"2014","unstructured":"Zhou M, et al. Separating tumorigenicity from bile Acid Regulatory activity for endocrine hormone FGF19. Cancer Res. 2014;74:3306\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0208.","journal-title":"Cancer Res"},{"key":"810_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","volume":"62","author":"NS Ghonem","year":"2015","unstructured":"Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62:635\u201343. https:\/\/doi.org\/10.1002\/hep.27744.","journal-title":"Hepatology"},{"key":"810_CR44","doi-asserted-by":"publisher","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","volume":"11","author":"E Henriksson","year":"2020","unstructured":"Henriksson E, Andersen B. FGF19 and FGF21 for the treatment of NASH-Two Sides of the same Coin? Differential and overlapping Effects of FGF19 and FGF21 from mice to human. Front Endocrinol (Lausanne). 2020;11:601349. https:\/\/doi.org\/10.3389\/fendo.2020.601349.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"810_CR45","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.celrep.2017.06.063","volume":"20","author":"Z Huang","year":"2017","unstructured":"Huang Z, et al. Uncoupling the mitogenic and metabolic functions of FGF1 by tuning FGF1-FGF receptor Dimer Stability. Cell Rep. 2017;20:1717\u201328. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.063.","journal-title":"Cell Rep"},{"key":"810_CR46","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/MCB.02249-06","volume":"27","author":"R Goetz","year":"2007","unstructured":"Goetz R, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007;27:3417\u201328. https:\/\/doi.org\/10.1128\/MCB.02249-06.","journal-title":"Mol Cell Biol"},{"key":"810_CR47","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.str.2017.06.016","volume":"25","author":"Y Liu","year":"2017","unstructured":"Liu Y, et al. Regulation of receptor binding specificity of FGF9 by an Autoinhibitory Homodimerization. Structure. 2017;25:1325\u20131336e1323. https:\/\/doi.org\/10.1016\/j.str.2017.06.016.","journal-title":"Structure"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-023-00810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-023-00810-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-023-00810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T05:15:18Z","timestamp":1700457318000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-023-00810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1186\/s12896-023-00810-9","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal care and all animal experiments conformed to the Guide for the Care and Use of Laboratory Animals provided by U.S. National Institutes of Health and was approved by the Animal Care and Use Committee of Wenzhou Medical University, China. All the Pre-clinical animal studies were reported in accordance with ARRIVE guidelines 2.0. All methods were carried out in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"43"}}